MOUNJARO® 7.5mg KwikPen®, 1 Stk.

MOUNJARO® 7.5mg KwikPen is a tirzepatide 7.5mg/0.6mL solution for injection from Eli Lilly and Company Limited, formulated as a once-weekly dual GIP and GLP-1 receptor agonist. Tirzepatide is the active substance, while MOUNJARO® is the brand name. This pre-filled KwikPen contains 4 doses and is used as an intermediate titration step between 5mg and 10mg. Are you looking to buy MOUNJARO® 7.5mg KwikPen online? Licensed professionals can contact the Doctor Medica staff for guidance and directions regarding product availability, documentation, and ordering.

Product Specifications

• Active Substance: Tirzepatide
• Strength: 7.5mg per dose, 0.6mL per dose
• Dosage Form: Solution for injection; 1 pre-filled KwikPen with 4 doses
• Manufacturer: Eli Lilly and Company Limited
• Brand: MOUNJARO®
• Country of Origin: United States
• FDA Approval Date: Initial US approval in 2022 for MOUNJARO® (tirzepatide) injection [1]
• Drug Class: Injectable dual GIP and GLP-1 receptor agonist
• Storage Requirements: Store refrigerated at 2°C to 8°C before use; do not freeze. After first use, the KwikPen may be stored unrefrigerated for up to 30 days at temperatures not above 30°C, according to UK product information. [2]
• Pack Sizes: Authorized presentations include a single pre-filled KwikPen (4 doses) and a 3-pen pack (each pen delivering 4 doses); practitioners should confirm which pack configuration applies in their market. [3]
• Package Dimensions: Width: 60mm | Height: 40mm | Length: 150mm | Weight: 60g

What is MOUNJARO® 7.5mg KwikPen?

MOUNJARO® 7.5mg KwikPen contains tirzepatide, a synthetic peptide with activity at both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Is MOUNJARO® tirzepatide? Yes. MOUNJARO® is Eli Lilly’s brand name, while tirzepatide is the active substance, also known as the international non-proprietary name (INN).

The 7.5mg dose is an intermediate titration strength used after the 5mg dose when clinical response warrants further dose escalation. It is not the starting dose. Each MOUNJARO® KwikPen 7.5mg dose contains 7.5mg of tirzepatide in 0.6mL of solution, and each multi-dose pre-filled KwikPen contains 4 once-weekly doses. [2]

This strength is used within a stepwise titration schedule designed to improve tolerability while supporting glycaemic and weight-related outcomes. Prescribers should assess blood sugar levels, gastrointestinal tolerability, renal function, comorbidities, and concomitant medicines before advancing from 5mg to 7.5mg or from 7.5mg to 10mg. [1][2]

Mechanism of Action

Tirzepatide acts through dual engagement of the GIP and GLP-1 receptors. GLP-1 receptor activation increases glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and helps reduce postprandial glucose excursions. GIP receptor activation also potentiates insulin release and may contribute to metabolic effects relevant to weight reduction and lipid handling. [1][2]

This dual mechanism distinguishes tirzepatide from single-pathway GLP-1 receptor agonists. In a head-to-head phase 3 trial, tirzepatide demonstrated statistically significant reductions in HbA1c and body weight compared with semaglutide 1mg, when both were used in combination with metformin. [2] Blood sugar levels are managed through a glucose-dependent mechanism, meaning the standalone risk of low blood sugar is generally low when tirzepatide is used without insulin or insulin secretagogues. In a placebo-controlled trial evaluating tirzepatide added to titrated basal insulin, however, the risk of hypoglycemia was meaningfully increased when tirzepatide was combined with insulin therapy. [5]

Gastrointestinal effects such as nausea, diarrhea, and vomiting remain clinically important during initiation and dose escalation. For the 7.5mg dose, prescribers should review current pharmacological data, contraindications, and the complete prescribing information before prescribing or adjusting therapy.

Indications & Clinical Use

MOUNJARO® is used in adults and eligible pediatric patients with type 2 diabetes as an adjunct to diet and exercise to improve glycaemic control. In the United States, MOUNJARO® is approved for type 2 diabetes, while tirzepatide’s chronic weight-management and obstructive sleep apnea indications are handled under the Zepbound® brand. [1][4]

In EU and UK product information, MOUNJARO® is indicated for type 2 diabetes and for weight management in eligible adults with obesity or overweight and at least one weight-related comorbid condition. Obstructive sleep apnoea is explicitly listed among the qualifying weight-related comorbidities, and the EU/UK label references dedicated clinical trial data on tirzepatide’s effect on apnoea-hypopnoea index in adults with obesity and moderate-to-severe OSA. Practitioners should verify the approved indication and label in their local jurisdiction before prescribing. [2][3]

The 7.5mg strength is a titration step between 5mg and 10mg. It may be appropriate when the 5mg dose has been tolerated, and additional glycaemic or weight-management response is clinically indicated. Before increasing the dose, the doctor or pharmacist should review gastrointestinal tolerability, blood sugar levels, renal status, cardiovascular history, baseline diabetic retinopathy, and the use of medications that may increase the risk of low blood sugar.

Administration & Injection Guidelines

MOUNJARO® 7.5mg KwikPen is administered once weekly by subcutaneous injection. Recommended injection sites include the abdomen, thigh, or upper arm. The same day each week is preferred, and injection sites should be rotated at each weekly administration to reduce local irritation. [1][2]

For professionals reviewing how to use MOUNJARO® KwikPen 7.5mg, the general technique involves checking the label and strength, inspecting the solution, selecting a clean injection site, preparing the pre-filled KwikPen according to the instructions for use, inserting the needle, activating the dose button, holding the pen in place as directed, and confirming dose delivery. Pharmacist or nurse counseling can help reinforce correct KwikPen technique, site rotation, storage, and disposal.

If a dose is missed, product information generally advises administering it as soon as possible within 4 days after the missed dose. If more than 4 days have passed, the missed dose should be skipped, and the next dose should be administered on the regularly scheduled day. A double dose should not be used to make up for a missed dose. [2]

MOUNJARO® does not require a specific food restriction on the label, but it is used alongside diet and exercise. Drug interaction review is important because tirzepatide delays gastric emptying and may affect the absorption of oral medicines, especially time-sensitive drugs or those with a narrow therapeutic index. [1][2]

Side Effects & Safety Considerations

Common side effects of MOUNJARO® 7.5mg include nausea, diarrhea, vomiting, decreased appetite, constipation, dyspepsia, and abdominal discomfort. These effects are predominantly gastrointestinal and are often most noticeable during dose initiation and escalation. Many GI reactions decrease over time, but monitoring is important in patients at risk of dehydration, renal impairment, frailty, or poor oral intake. [1][2]

Low blood sugar is more likely when MOUNJARO® is used with insulin or sulfonylureas. In these cases, clinicians may need to adjust companion therapy and monitor blood sugar levels more closely. Serious but less common risks include pancreatitis, gallbladder disease, hypersensitivity reactions, and kidney damage associated with dehydration from severe nausea, diarrhea, or vomiting. [1][2]

Patients with signs of pancreatitis, such as persistent severe abdominal pain with or without vomiting, require prompt medical assessment. Patients who accidentally use too much MOUNJARO® should seek medical attention because an overdose may increase the risk of gastrointestinal adverse events and hypoglycemia, especially when used with other glucose-lowering medicines.

In the US, MOUNJARO® carries a boxed warning and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, based on thyroid C-cell tumor findings in rodent studies; human relevance of this finding has not been established. [1] Hypersensitivity to tirzepatide or any of its formulation components is a contraindication across markets. [1][2] Prescribers should review the current, market-specific prescribing information for the complete list of contraindications, warnings, and safety data, as the scope of contraindications can differ between the US label and EU/UK product information.

MOUNJARO® KwikPen 7.5mg Price and Legal Status

MOUNJARO® is a prescription-only pharmaceutical product. In the US, MOUNJARO® is FDA-approved for glycaemic control in type 2 diabetes, whereas tirzepatide’s chronic weight management and OSA indications are associated with Zepbound®. In the EU and UK, product information includes type 2 diabetes and weight-management indications, with local access depending on the applicable label and country-level requirements. [1][2][3][4] This content is current as of July 1, 2026, and the doctor or pharmacist should verify current regulatory requirements before prescribing, dispensing, or sourcing.

MOUNJARO® KwikPen 7.5mg price may vary by jurisdiction, supply channel, account status, pack size, documentation requirements, and cold-chain handling needs. Licensed professionals can contact Doctor Medica staff to check for wholesale buying options and to confirm current product information, professional requirements, and handling guidance. Those looking to buy MOUNJARO® KwikPen wholesale should verify authenticity documentation, local labeling, storage standards, and prescribing requirements when buying online. Practices evaluating tirzepatide as part of a broader obesity-care portfolio may also want to buy weight loss products as part of the same sourcing review.

Citations

1. US Food and Drug Administration. MOUNJARO® Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215866s039lbl.pdf
2. Electronic Medicines Compendium. Mounjaro KwikPen 7.5mg Solution for Injection in Pre-filled Pen: Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/15483/smpc
3. European Medicines Agency. Mounjaro: EPAR Product Information. https://www.ema.europa.eu/en/documents/product-information/mounjaro-epar-product-information_en.pdf
4. US Food and Drug Administration. FDA Approves First Medication for Obstructive Sleep Apnea. Published December 20, 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea
5. Dahl D, Onishi Y, Norwood P, et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. Journal of the American Medical Association. 2022. https://pubmed.ncbi.nlm.nih.gov/35133415/

For licensed medical professionals only. This content is for informational purposes only and does not constitute medical advice.